SecBot SecBot
S-3 ·Filed Oct 27, 2026

TELO

Telomir Pharmaceuticals, Inc.
NEUTRAL
Impact 4/10
Processed6h 38m ago SEC0001493152-26-048714
Shelf registration — potential dilution

Price Chart

Loading chart...

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001493152-26-048714
Exhibit: ex107.htm0001493152-26-048714
Exhibit: ex5-1.htm0001493152-26-048714
Exhibit: ex23-1.htm0001493152-26-048714
Document: 0001493152-26-048714-index-headers.html0001493152-26-048714
Document: 0001493152-26-048714-index.html0001493152-26-048714
Document: 0001493152-26-048714.txt0001493152-26-048714
10 reports for TELO
Performance horizon
Filters
Rows
Reports for TELO — sortable, filterable
TypeNow
Oct 27, 2026
today
S-3
NEUTRAL ★ 4/10
$1.03awaiting T+20—$1.02 (−0.97%)
Oct 6, 2026
21d ago
8-K
NEUTRAL ★ 5/10
$1.20awaiting T+20—$1.02 (−15.00%)
Sep 17, 2026
5w ago
8-K
NEUTRAL ★ 4/10
$1.12 $1.05▼ −6.25%▼ −7.46%$1.02 (−8.93%)
Sep 17, 2026
5w ago
Press Release
NEUTRAL ★ 4/10
$1.12 $1.05▼ −6.25%▼ −7.71%$1.02 (−8.93%)
Sep 14, 2026
6w ago
8-K
NEUTRAL ★ 4/10
$1.17 $1.10▼ −5.98%▼ −8.25%$1.02 (−12.82%)
Aug 19, 2026
9w ago
DEFA14A
NEUTRAL ★ 2/10
$1.17 $1.12▼ −4.27%▼ −2.32%$1.02 (−12.82%)
Aug 10, 2026
11w ago
8-K
NEUTRAL ★ 4/10
$1.17 $1.19▲ +1.71%▲ +2.62%$1.02 (−12.82%)
Jun 15, 2026
19w ago
8-K
NEUTRAL ★ 3/10
$1.29 $1.24▼ −3.88%▼ −3.13%$1.02 (−20.93%)
Jun 8, 2026
20w ago
8-K
NEUTRAL ★ 2/10
$1.21 $1.24▲ +2.48%▲ +1.03%$1.02 (−15.70%)
Apr 24, 2026
26w ago
8-K
MIXED ★ 7/10
$1.40 $1.30▼ −7.14%▼ −11.17%$1.02 (−27.14%)
Showing 10 of 10

US Market Status

Market Closed — Opens Thu (10h 20m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 27, 2026

Fresh TELO Intelligence

Analysis is for subscribers only.

Subscribe for Full Access